Informed consent in dementia trials presents a fundamental ethical challenge: how do you obtain voluntary, informed agreement from someone whose cognitive decline may prevent them from understanding the research? The answer involves a dual approach combining capacity assessment with surrogate decision-making. In practice, when a person with early-stage dementia enrolls in a hypothetical Alzheimer’s drug trial, researchers must first evaluate whether that person can understand the study’s purpose, risks, and benefits. If capacity is present but limited, simplified consent documents and repeated consent conversations may be used.
If capacity is absent, a spouse, adult child, or court-appointed surrogate steps in—but even then, the person’s own evolving wishes must still guide the process. This dual framework exists because neither capacity alone nor surrogate decision-making alone is sufficient. A person with mild cognitive impairment might retain the ability to consent to low-risk observational studies while lacking capacity for invasive procedures. Conversely, a surrogate’s decision, no matter how well-intentioned, cannot simply override a person’s own documented preferences or current expressions of refusal.
Table of Contents
- Can Someone with Dementia Understand a Research Study?
- The Limitations of Capacity-Based Consent Alone
- The Role of Surrogates in Dementia Research
- Practical Approaches to Obtaining and Documenting Consent
- Ongoing Consent and the Right to Withdraw
- Advance Directives and Research Preferences
- The Challenge of Research with Vulnerable Populations
- Frequently Asked Questions
Can Someone with Dementia Understand a Research Study?
Capacity assessment in dementia research focuses on four key abilities: understanding the information presented, appreciating how it applies to oneself, reasoning through the decision, and expressing a choice. A 73-year-old woman with moderate Alzheimer’s disease might understand that a drug trial involves taking a medication twice daily and having blood drawn monthly. She might even appreciate that this could help her memory. But if she cannot reason through whether the medication’s possible side effects (nausea, dizziness) matter more or less than the potential benefit, her capacity becomes questionable.
Capacity is not binary—it exists on a spectrum and can fluctuate with time of day, medication effects, or disease progression. Research teams use standardized tools like the MacCAT-CR (MacArthur Competence Assessment Tool for clinical Research) or the Capacity to Consent to Treatment Instrument to measure these abilities. These assessments ask the person specific questions about the study and score responses, but they also require clinical judgment. A person who scores below a threshold on a formal tool might still retain enough understanding to participate in a low-risk study, whereas someone scoring higher might lack capacity for higher-risk research. This nuance means that capacity is decision-specific and context-dependent, not a global determination.
The Limitations of Capacity-Based Consent Alone
Even when a person with dementia demonstrates sufficient capacity, their consent may be unstable or reversible. Someone who understands a trial at enrollment might forget they agreed to it within days or weeks as their disease progresses. This creates a gap: the consent was genuine at the moment it was given, but the person’s ability to maintain that consent or withdraw it becomes compromised. Some trials address this through periodic re-consent conversations, where researchers check in at intervals to ensure the person still understands and agrees. However, this approach has a practical limit—repeating the same complex information constantly can feel burdensome and may not be ethically justified if the person’s medical situation hasn’t changed.
Another limitation is the influence of hope and research enthusiasm. A person with early dementia, desperate for a treatment, might minimize or discount risks in their mind. They might overestimate the likelihood that an experimental drug will help them personally, a phenomenon called therapeutic misconception. Researchers cannot simply accept a person’s capacity-based consent at face value; they must actively work to ensure the person has realistic expectations. This requires spending time with the person, asking open-ended questions about their understanding, and gently correcting misunderstandings without pressuring them to change their decision.
The Role of Surrogates in Dementia Research
When a person with dementia lacks capacity to consent, the law and ethics typically recognize a hierarchy of surrogate decision-makers. A legal healthcare proxy or power of attorney holder comes first, followed by a spouse, adult children, parents, and siblings in order. The surrogate’s job is not to decide what they would choose for themselves, but to apply one of two standards: the “substituted judgment” standard (what the person would have chosen if they could decide now) or the “best interest” standard (what choice would be most beneficial to the person, considering their values and circumstances).
In practice, these standards often overlap. A wife serving as surrogate for her husband with moderate-stage Alzheimer’s disease will consider what he said about research before his illness. He might have mentioned, “I want to help other people find a cure.” That expressed value guides the substituted judgment. But she will also weigh the study’s actual risks—is it asking him to undergo an invasive procedure that would frighten him? Is there a reasonable chance of direct benefit? These best-interest considerations temper the substituted judgment, creating a blend of both standards.
Practical Approaches to Obtaining and Documenting Consent
Research teams working with people who have dementia increasingly use multimodal consent processes. Instead of one consent conversation, there are multiple interactions: a family meeting with the surrogate, a separate conversation with the person themselves (even if they lack full capacity), written consent forms in plain language, and visual or video explanations of the study. Some trials now use comic-style illustrated consent forms or video explanations, recognizing that traditional dense consent documents are understood by few people, let alone those with cognitive impairment.
Documenting capacity assessment and the consent process is equally important. Rather than simply having the person sign a form, research records should include notes on which capacity elements were assessed, whether formal testing was used, and how the information was presented. If a surrogate gave consent, the record should document how they were identified as the appropriate surrogate, what standard they applied, and whether the person with dementia was involved in the discussion. This documentation protects both the research participant and the researchers, creating a clear record that the process was ethical and deliberate.
Ongoing Consent and the Right to Withdraw
A common misconception is that once consent is obtained, it is fixed for the duration of a trial. In reality, informed consent is a continuing process. At each study visit, researchers should assess whether the person with dementia still understands what they’re participating in and still agrees. If a person who previously consented becomes upset at the sight of study procedures, or begins refusing blood draws, that resistance is meaningful—it may reflect a change in their understanding or preferences, or simply a change in emotional state that signals discomfort. Withdrawal from a study by a person with advanced dementia raises complex questions.
If the person cannot meaningfully consent to a study, can they meaningfully withdraw from it? Most ethical frameworks say yes. A person who expresses distress or refusal has effectively withdrawn, even if they cannot articulate the reason. However, a surrogate also retains the right to withdraw. A daughter might decide that her father’s declining condition makes continued study participation too burdensome, even if he cannot express that himself. The tension arises when the person’s expressed wishes conflict with the surrogate’s judgment—a scenario requiring careful team discussion and, sometimes, institutional review board involvement.
Advance Directives and Research Preferences
Some people with early-stage dementia use advance directives to document their research preferences before capacity is lost. These directives might specify that they wish to participate in Alzheimer’s research to advance science, or conversely, that they prefer not to enroll in any trials. An advance directive is a powerful tool because it reflects the person’s autonomous choice made while they had full decision-making capacity, and it binds surrogates to those preferences even if the surrogate disagrees.
A 69-year-old man diagnosed with mild cognitive impairment might complete an advance directive stating, “I want to participate in any Alzheimer’s research that does not require major surgery.” When he later loses capacity, his surrogate uses this directive as the template for decisions. If a trial involving lumbar puncture is proposed, the surrogate can reference his stated preferences to decline. This approach respects the person’s earlier self and reduces the burden on surrogates to guess what the person would have wanted.
The Challenge of Research with Vulnerable Populations
Dementia research requires special protections precisely because it involves vulnerable participants. Federal regulations, such as 45 CFR 46 in the United States, include additional safeguards for research involving cognitively impaired people. Institutional review boards must specifically consider whether the risks are reasonable in relation to anticipated benefits, whether the consent process is adequate, and whether there are additional protections—such as a research advocate or independent ombudsman—to monitor the participant’s welfare during the study. A key protection is the requirement that research benefits be proportional to risks when participants cannot consent.
A person with advanced dementia cannot enroll in a high-risk drug trial unless there is a reasonable chance they will personally benefit from the treatment. Research that seeks knowledge about dementia but offers no direct benefit to participants is restricted to those with capacity to consent. This means much dementia research must involve people in earlier disease stages, who may have better capacity but less severe symptoms. This limitation affects the types of studies that can be conducted and the populations they can include.
Frequently Asked Questions
What does “capacity to consent” mean in a dementia trial?
Capacity means the ability to understand study information, appreciate how it applies to you, reason through the decision, and express a choice. It’s assessed using standardized tools and clinical judgment, and it’s decision-specific—someone might have capacity for one study but not another.
If someone with dementia has a surrogate, can the surrogate decide anything about the trial?
No. Surrogates must apply substituted judgment (deciding as the person would have) or best-interest standards, and they cannot make choices that conflict with the person’s documented preferences or expressed wishes. Some decisions, like enrolling in high-risk trials with no direct benefit, are restricted.
Can a person with dementia withdraw from a research study?
Yes. Ongoing consent is required throughout a trial. If the person expresses refusal or distress, that signals withdrawal even if they cannot explain it. A surrogate can also withdraw the person from a study at any time.
Should a person complete an advance directive about research before dementia develops?
Advance directives are valuable. They document your preferences about research participation while you have full capacity, guiding future surrogates and ensuring your autonomous wishes are honored even after you lose decision-making ability.
Are people with dementia ever excluded from research?
High-risk research with no direct benefit to participants may be limited to those with capacity. However, observational studies, lower-risk intervention trials, and studies with clear personal benefit may include people with dementia whose surrogates consent according to ethical standards.
What happens if a surrogate’s choice conflicts with the person’s expressed wishes?
The person’s expressed wishes generally take priority. If a person with dementia says “no” to a procedure despite a surrogate’s consent, that refusal is respected. Conflicts may require ethics consultation or institutional review board guidance.
